Experimental drug PMG1015 tested for lung scarring disease
Disease control
Completed
This early-phase trial tested an experimental drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal was to check the drug's safety and how the body processes it, not whether it works. Participants received either PMG1015…
Phase: PHASE1 • Sponsor: Pulmongene Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC